Moderna Puts Its First Seasonal Flu Vaccine In The Clinic

  • Moderna Inc MRNA has initiated a Phase 1/2 study and dosed the first patient with mRNA1010, its quadrivalent vaccine for seasonal flu.
  • The candidate is designed to target lineup lineages that include influenza A H1N1, H3N2, and influenza B Yamagata and Victoria.
  • The 180-subject study will evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010.
  • Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Moderna with a $246 price target after initiating a Phase 1 study of mRNA-1010. 
  • Moderna could "revolutionize" the seasonal flu vaccine market where today's protection rates are only 40%-60%, Tenthoff writes in a research note. 
  • Ultimately Moderna envisions developing a respiratory vaccine that protects against seasonal flu, Covid, and respiratory syncytial virus, says the analyst.
  • Price Action: MRNA shares are down 4.95% at $221.80 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsHealth CarePrice TargetAnalyst RatingsGeneralBriefsEdward TenthoffPiper Sandler
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!